Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.41 |
| ▸ | CES1 | P23141 | 1/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.39 |
| ▸ | FFAR3 | O14843 | 3/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | GAPDH | P04406 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3247486 | 1.00 | CES2 (0.41) | CES2CES1HDAC3HDAC1HDAC2 | |
| SCHEMBL11716989 | 0.82 | — | — | |
| SCHEMBL4052430 | 0.81 | CES2 (0.31) | CES2CES1HDAC3HDAC1HDAC2 | |
| SCHEMBL27723087 | 0.80 | — | — | |
| SCHEMBL14860085 | 0.75 | — | — | |
| SCHEMBL28340228 | 0.75 | CES2 (0.47) | CES2CES1HDAC3HDAC1HDAC2 | |
| SCHEMBL1822063 | 0.72 | — | — | |
| SCHEMBL1820884 | 0.72 | — | — | |
| SCHEMBL28164230 | 0.72 | — | — | |
| SCHEMBL107483 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1439177-B1 | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane | UNIV EMORY (US) | 2010-05-26 | — | — | EP | disclosed |
| US-20090048190-A1 | Antiviral activity and resolution of 2-hydroxymethyl-5(5-fluorocytosin-1-yl)-1,3-oxathiolane | LIOTTA DENNIS C | 2009-02-19 | — | — | US | disclosed |
| US-7402588-B2 | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane | EMORY UNIVERSITY (US) | 2008-07-22 | — | — | US | disclosed |
| US-20060276492-A1 | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane | LIOTTA DENNIS C | 2006-12-07 | — | — | US | disclosed |
| US-20050215527-A1 | Antiviral activity and resolution of 2-hydroxymethyl-5- (5-fluorocytosin-1-yl)-1, 3-oxathiolane | EMORY UNIVERSITY | 2005-09-29 | — | — | US | disclosed |
| US-20050004148-A1 | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane | EMORY UNIVERSITY | 2005-01-06 | — | — | US | disclosed |
| EP-1439177-A1 | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane | EMORY UNIVERSITY (US) | 2004-07-21 | — | — | EP | disclosed |
| US-6642245-B1 | Treatment of HIV and HBV infections in humans | EMORY UNIVERSITY | 2003-11-04 | — | — | US | disclosed |
| EP-0984013-A2 | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1, 3-oxathiolane | EMORY UNIVERSITY (US) | 2000-03-08 | — | — | EP | disclosed |
| US-5914331-A | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane | EMORY UNIVERSITY (US) | 1999-06-22 | — | — | US | disclosed |
| EP-0575482-A1 | ANTIVIRAL ACTIVITY AND RESOLUTION OF 2-HYDROXYMETHYL-5-(5-FLUOROCYTOSIN-1-YL)-1,3-OXATHIOLANE | EMORY UNIVERSITY (US) | 1993-12-29 | — | — | EP | disclosed |
| WO-1992014743-A2 | ANTIVIRAL ACTIVITY AND RESOLUTION OF 2-HYDROXYMETHYL-5-(5-FLUOROCYTOSIN-1-YL)-1,3-OXATHIOLANE | EMORY UNIVERSITY (US) | 1992-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004148-A1 | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane | PNP, MTAP, ENTPD5 | CES2 61/4885CES1 20/4885HDAC3 2699/4885 |
| US-20060276492-A1 | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane | PNP, MTAP, ENTPD5 | CES2 61/4885CES1 20/4885HDAC3 2699/4885 |
| US-20090048190-A1 | Antiviral activity and resolution of 2-hydroxymethyl-5(5-fluorocytosin-1-yl)-1,3-oxathiolane | PNP, MTAP, ENTPD5 | CES2 62/4885CES1 23/4885HDAC3 2837/4885 |
| US-20050215527-A1 | Antiviral activity and resolution of 2-hydroxymethyl-5- (5-fluorocytosin-1-yl)-1, 3-oxathiolane | PNP, MTAP, ENTPD5 | CES2 61/4885CES1 20/4885HDAC3 2699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.